Literature DB >> 6349427

Community-acquired bacterial pneumonia requiring admission to hospital.

J J Klimek, E Ajemian, S Fontecchio, J Gracewski, B Klemas, L Jimenez.   

Abstract

Patients who develop bacterial pneumonia in the community often require admission to acute-care hospitals. Knowledge of the incidence of pneumonia due to different pathogens that are brought into an institution from the community may play a role in determining the patterns of infecting organisms responsible for hospital-acquired pneumonia. For 1 year, we prospectively reviewed the records of patients admitted to our 1000-bed community hospital with community-acquired bacterial pneumonia (CABP). Patients had clinical signs and symptoms, positive radiologic findings, and pure cultures of potential pathogens from sputum, blood, pleural fluid, lung aspirate, lung biopsy, or transtracheal aspirate. Pneumonia due to Legionella pneumophila was diagnosed by serum indirect fluorescent antibody (IFA) titer greater than or equal to 1:256 and clinical signs and symptoms along with response to erythromycin. Of 204 patients with bacterial pneumonia, the following pathogens were implicated: Streptococcus pneumoniae, Haemophilus species, L. pneumophila, Staphylococcus aureus, Klebsiella pneumoniae, Escherichia coli, oral anaerobic bacteria, Psuedomonas aeruginosa, Serratia marcescens, and others. Most patients were more than 50 years of age and many had evidence of underlying pulmonary disease. The etiology of CABP may not be as predictable as in the past. Empiric antimicrobial therapy for CABP should include agents with activity against the pathogens prevalent in the community.

Entities:  

Mesh:

Year:  1983        PMID: 6349427     DOI: 10.1016/0196-6553(83)90117-7

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  5 in total

1.  Pneumococcal community-acquired pneumonia in 148 hospitalized adult patients.

Authors:  A Porath; F Schlaeffer; N Pick; M Leinonen; D Lieberman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-12       Impact factor: 3.267

2.  Comparison of cefdinir and cefaclor in treatment of community-acquired pneumonia.

Authors:  M Drehobl; P Bianchi; C H Keyserling; K J Tack; T J Griffin
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

3.  Ampicillin versus cefamandole as initial therapy for community-acquired pneumonia.

Authors:  D J Weber; S B Calderwood; A W Karchmer; J E Pennington
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

4.  Randomized comparative trial with ampicillin/sulbactam versus cefamandole in the therapy of community acquired pneumonia.

Authors:  D Williams; M Perri; M J Zervos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-04       Impact factor: 3.267

5.  Epidemiology of community-acquired respiratory tract infections in adults. Incidence, etiology, and impact.

Authors:  R A Garibaldi
Journal:  Am J Med       Date:  1985-06-28       Impact factor: 4.965

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.